As FGFR-TACC fusions, specifically FGFR3-TACC3, are the most common gene fusions reported in GBM, the discussions in this section will be focused on the therapeutic value of targeting FGFR3-TACC3 in GBM. This evidence concerns the gene FGFR3 and glioblastoma.